Literature DB >> 6995091

Adverse antibiotic drug interactions.

A J Bint, I Burtt.   

Abstract

There is enormous potential for drug interactions in patients who, today, often receive many drugs. Antibiotics are prominent amongst the groups of drugs commonly prescribed. Many interactions take place at the absorption stage. Antacids and antidiarrhoeal preparations, in particular, can delay and reduce the absorption of antibiotics such as tetracyclines and clindamycin, by combining with them in the gastrointestinal tract to form chelates or complexes. Other drugs can affect gastric motility, which in turn often controls the rate at which antibiotics are absorbed. Some broad spectrum antibiotics can alter the bacterial flora of the gut which may be related to malabsorption states. The potentiation of toxic side effects of one drug by another is a common type of interaction. Antibiotics which are implicated in this type of interaction are those which themselves possess some toxicity such as aminoglycosides, some cephalosporins, tetracyclines and colistin. Some of the most important adverse interactions with antibiotics are those which involve other drugs which have a low toxicity/efficacy ratio. These include anticoagulants such as warfarin, anticonvulsants such as phenytoin and phenobarbitone and oral antidiabetic drugs like tolbutamide. Risk of interaction arises when the metabolism of these drugs is inhibited by liver microsomal enzyme inhibitors such as some sulphonamides and chloramphenicol, or is enhanced by enzyme inducers such as rifampicin.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6995091     DOI: 10.2165/00003495-198020010-00004

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  58 in total

1.  Neostigmine therapy for apnea occurring after administration of neomycin; report of a case.

Authors:  W H MIDDLETON; D D MORGAN; J MOYERS
Journal:  J Am Med Assoc       Date:  1957-12-28

2.  The stereoselective interaction of warfarin and metronidazole in man.

Authors:  R A O'Reilly
Journal:  N Engl J Med       Date:  1976-08-12       Impact factor: 91.245

3.  Effects of antacids on gastrointestinal absorption of isoniazid in rat and man.

Authors:  A Hurwitz; D L Schlozman
Journal:  Am Rev Respir Dis       Date:  1974-01

4.  [Effects of rifampicin on the menstrual cycle and on oestrogen excretion in patients taking oral contraceptives].

Authors:  L Nocke-Finck; H Breuer; D Reimers
Journal:  Dtsch Med Wochenschr       Date:  1973-08-11       Impact factor: 0.628

5.  Maternal oestrogen levels during penicillin treatment.

Authors:  M Pulkkinen; K Willman
Journal:  Br Med J       Date:  1971-10-02

6.  Enhancement by potent diuretics of renal tubular necrosis induced by cephaloridine.

Authors:  M G Dodds; R D Foord
Journal:  Br J Pharmacol       Date:  1970-10       Impact factor: 8.739

7.  Aspects of pharmacokinetics and biopharmaceutics in relation to drug activity.

Authors:  J G Wagner
Journal:  Am J Pharm Sci Support Public Health       Date:  1969 Jan-Feb

8.  Ototoxicity of ethacrynic acid and aminoglycoside antibiotics in uremia.

Authors:  R H Mathog; W J Klein
Journal:  N Engl J Med       Date:  1969-05-29       Impact factor: 91.245

9.  Pharmacokinetic evaluation of a drug interaction between kaolin--pectin and clindamycin.

Authors:  K S Albert; K A DeSante; R D Welch; A R DiSanto
Journal:  J Pharm Sci       Date:  1978-11       Impact factor: 3.534

10.  Displacement of warfarin from human albumin by diazoxide and ethacrynic, mefenamic, and nalidixic acids.

Authors:  E M Sellers; J Koch-Weser
Journal:  Clin Pharmacol Ther       Date:  1970 Jul-Aug       Impact factor: 6.875

View more
  2 in total

Review 1.  Adverse drug interactions.

Authors:  M J Brodie; J Feely
Journal:  Br Med J (Clin Res Ed)       Date:  1988-03-19

2.  Unusual presentation of iatrogenic phenytoin toxicity in a newborn.

Authors:  Jennifer A Lowry; John C Vandover; Jan DeGreeff; Anthony J Scalzo
Journal:  J Med Toxicol       Date:  2005-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.